---
document_datetime: 2025-10-17 12:20:50
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/polivy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: polivy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6280773
conversion_datetime: 2025-12-20 13:05:49.29533
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Polivy

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 16/10/2025                          |                                             | SmPC and PL                      | To remove from the Product Information the black |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000295634                     | PRODUCTS - C.I.z Other variation - Accepted C.I.z (Type IB) - To remove from the Product Information the black symbol and explanatory statements for medicinal products subject to additional monitoring. Additionally, Section 5.1 of the EU SmPC is updated with information on patients with DLBCL in study GO39942 (POLARIX), which was approved for the EN SmPC with procedure EMEA/H/C/004870/II/0012, but was not yet included in the EU SmPC. Furthermore, the MAH took the opportunity to implement editorial changes throughout the PI to align with the QRD template and updated the list of local representatives in the PL.   |            |     | symbol and explanatory statements for medicinal products subject to additional monitoring. Additionally, Section 5.1 of the EU SmPC is updated with information on patients with DLBCL in study GO39942 (POLARIX), which was approved for the EN SmPC with procedure EMEA/H/C/004870/II/0012, but was not yet included in the EU SmPC.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000254622 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted                                                                                                                  | 27/03/2025 | N/A |                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000240448   | 21/01/2025   | N/A   |
|-----------------------------------------|--------------|-------|